BetterMe Rx Semaglutide Cost: 2026 Pricing and Plans Compared

Last reviewed: September 1, 2026 Last updated: September 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

PlexusDx publishes this comparison and is one of the providers discussed. We use the same evidence rules for our own program and competing programs.

The short answer

BetterMe Rx does not publish semaglutide pricing on its website. As of July 20, 2026, pricing becomes visible only after completing an intake questionnaire, and we had not completed checkout verification to capture actual costs. This creates a decision problem: you cannot compare total costs, evaluate billing structures, or calculate 12-month outlays without completing BetterMe Rx's intake process first. If pricing transparency before questionnaire completion matters to your decision workflow, BetterMe Rx's current approach does not support it.

What we know about BetterMe Rx semaglutide pricing

This represents the complete pricing evidence available in our sources as of the capture date shown. No month-to-month rate, no committed-term structure, no ancillary fees—nothing a cost-conscious buyer can convert into a 12-month projection.

Why pricing transparency matters before intake

Most telehealth weight-management programs publish at least a month-to-month rate before requiring personal information. That baseline enables apples-to-apples cost comparison: you calculate annual outlays, compare billing structures, and evaluate whether committing to multi-month terms offers meaningful savings. When pricing appears only after questionnaire completion, you must invest time and disclosure before knowing whether the program fits your budget. If BetterMe Rx's eventual price turns out higher than alternatives, you've spent intake effort you cannot recover.

Questionnaire-gated pricing also prevents third-party verification. We cannot confirm that prices remain stable across different intake profiles or geographic markets. Programs that show one price to one profile and another to a different profile fragment the market in ways that defeat like-for-like comparison. Until checkout verification completes, we cannot rule out that possibility here.

Comparison framework: what you can know upfront elsewhere

For context, here is what checkout-verified transparency looks like. PlexusDx publishes standard ongoing rates and pricing structures publicly:

The 12-month figure is our calculation: $189 × 12. That multiplication is possible only because the underlying monthly rate is published and verified. You cannot perform the same calculation for BetterMe Rx because the input does not exist in public evidence.

Decision factors when pricing is unknown

Choosing a weight-management program without published pricing introduces risk that published-pricing programs do not carry:

• Budget uncertainty: You cannot confirm affordability before intake. If BetterMe Rx's eventual price exceeds your budget, you learn that only after disclosing health information.
• Comparison friction: Like-for-like cost comparison requires converting both programs to the same billing term and calculating 12-month totals. Impossible when one program publishes nothing.
• Verification lag: Our sources had not completed checkout verification as of July 20, 2026. That gap means we cannot confirm dose-price relationships, membership fees, or cancellation terms—all of which affect total cost of ownership.
• Market-wide norms: Most U.S. telehealth GLP-1 programs now publish at least month-to-month rates. Questionnaire-gated pricing runs counter to that trend and may signal a pricing model that varies by intake profile.

None of these factors alone disqualifies BetterMe Rx. They describe the information environment you operate in when pricing is not public. If you already intend to complete BetterMe Rx's questionnaire for clinical reasons—perhaps you value its intake design or care model—pricing opacity may not matter. But if cost is a primary selection criterion, you will gather better evidence faster from programs that publish verified rates upfront.

What remains unknown

The following questions cannot be answered from available evidence as of July 20, 2026:

• What does BetterMe Rx charge per month for compounded semaglutide?
• Does pricing differ by dose level (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg)?
• Is there a membership fee, setup charge, or provider-visit fee separate from medication cost?
• Does BetterMe Rx offer committed-term billing (3-month, 6-month) at lower per-month equivalents?
• What is included in the advertised price (medication, shipping, provider access, supplies)?
• What are the cancellation and refund policies?
• Do prices vary by state or patient profile?

If these questions matter to your decision, you must either complete BetterMe Rx's intake to reveal pricing or select a program that answers them publicly.

Choose BetterMe Rx if…

• You prioritize clinical intake design or care-model features over pricing transparency before questionnaire completion.
• You are willing to disclose personal health information before learning total costs.
• You have already researched BetterMe Rx's service model through other channels and are confident in fit regardless of eventual price.

Choose a published-pricing program if…

• You want to calculate and compare 12-month costs before starting any intake process.
• Budget certainty matters more than questionnaire design or brand preference.
• You value third-party verification that pricing remains stable across different patient profiles.
• You want to confirm there are no hidden membership fees, setup charges, or dose-tier pricing before sharing personal information.

Where PlexusDx fits

PlexusDx publishes standard ongoing rates publicly: $189/month for compounded semaglutide injection, month-to-month, with no membership fee and same price at every dose. That yields a 12-month cost of $2,268 on the month-to-month term (our calculation). Lower committed-term rates are available for 3-month and 6-month prepaid plans. Pricing, billing structure, inclusions, dose policy, and cancellation terms are all documented before intake begins. A licensed provider still reviews fit—approval is required before any charge posts—but you know the cost structure before that clinical step starts.

PlexusDx works with licensed 503A compounding pharmacies. Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient.

Methodology and freshness

We captured BetterMe Rx website data on July 20, 2026. The source documented that semaglutide pricing was not published publicly and that checkout verification had not been completed as of that date. PlexusDx pricing was captured on the same date from live product pages. All 12-month cost calculations in this article are our own arithmetic, derived by multiplying documented monthly rates by twelve. We use standard ongoing rates and prepaid totals only, verified at the dates shown. If you encounter different pricing at checkout, that conflict may indicate a rate change after our capture date, profile-specific pricing, or geographic variation. Confirm all figures at checkout before committing.

Frequently Asked Questions

Why doesn't BetterMe Rx publish semaglutide pricing on its website?

We do not have an official statement from BetterMe Rx explaining the decision. Many telehealth programs gate pricing behind intake questionnaires to tailor offers to individual clinical profiles or to reduce price-shopping before clinical qualification. The trade-off is that prospective patients cannot compare total costs before starting the intake process.

Can I get a cost estimate from BetterMe Rx without completing the full questionnaire?

Not from public evidence as of July 20, 2026. Pricing visibility required questionnaire completion on that date. Whether partial or abbreviated intake paths exist is not documented in our sources. Contacting BetterMe Rx directly may yield an estimate, but we cannot verify that practice from available evidence.

How does questionnaire-gated pricing affect cost comparison?

It prevents like-for-like comparison until you complete intake. You cannot calculate 12-month totals, evaluate billing-term trade-offs, or confirm there are no hidden fees without first disclosing personal health information. Programs that publish month-to-month rates allow that analysis before intake begins.

What should I do if I need a budget ceiling before starting any intake?

Select a program that publishes verified month-to-month pricing publicly. Calculate the 12-month cost (monthly rate times twelve) and confirm that figure fits your budget. Then complete intake knowing the cost structure in advance. If the program requires provider approval, no charge posts until that approval completes, but the price itself is never a surprise.

Will PlexusDx pricing remain $189/month for semaglutide injection?

We captured that rate on July 20, 2026. Rates may change over time. Confirm current pricing on the PlexusDx product page before starting intake. If the figure has changed, the product page will reflect the update, and you can calculate a new 12-month total from the current rate before proceeding.

Sources

• PlexusDx internal research: BetterMe Rx and PlexusDx comparison data (accessed July 20, 2026)
• PlexusDx product pages: semaglutide injection and tirzepatide injection pricing (accessed July 20, 2026)

Compounded medication disclosure: Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.